KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Retained Earnings: 2011-2025

Historic Retained Earnings for Travere Therapeutics (TVTX) over the last 14 years, with Sep 2025 value amounting to -$1.5 billion.

  • Travere Therapeutics' Retained Earnings fell 6.38% to -$1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.5 billion, marking a year-over-year decrease of 6.38%. This contributed to the annual value of -$1.4 billion for FY2024, which is 28.57% down from last year.
  • According to the latest figures from Q3 2025, Travere Therapeutics' Retained Earnings is -$1.5 billion, which was up 1.71% from -$1.5 billion recorded in Q2 2025.
  • Travere Therapeutics' Retained Earnings' 5-year high stood at -$639.7 million during Q1 2021, with a 5-year trough of -$1.5 billion in Q2 2025.
  • For the 3-year period, Travere Therapeutics' Retained Earnings averaged around -$1.3 billion, with its median value being -$1.3 billion (2024).
  • Data for Travere Therapeutics' Retained Earnings shows a maximum YoY slumped of 53.92% (in 2021) over the last 5 years.
  • Travere Therapeutics' Retained Earnings (Quarterly) stood at -$766.0 million in 2021, then crashed by 32.41% to -$1.0 billion in 2022, then dropped by 10.98% to -$1.1 billion in 2023, then decreased by 28.57% to -$1.4 billion in 2024, then fell by 6.38% to -$1.5 billion in 2025.
  • Its last three reported values are -$1.5 billion in Q3 2025, -$1.5 billion for Q2 2025, and -$1.5 billion during Q1 2025.